New randomized, controlled trials “are needed” that compare metabolic bariatric surgery with medical and lifestyle management that includes “high-dose incretin-hormone therapy,” commented Robert H. Eckel, an endocrinologist and emeritus professor at the University of Colorado School of Medicine in Aurora.